Podcasts about CRISPR

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines's history-making IPO. We dive into the drug developer's plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates. Turning to some newly published research, we discuss the early results of a first-in-human clinical trial that is testing a dual vaccine against Lassa fever and rabies, a CRISPR system engineered to selectively trigger cancer cell death by chromatin shredding, and a novel mRNA delivery platform for delivering gene therapies starting with Duchenne muscular dystrophy. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPOBy Alex Philippidis, GEN Edge, June 14, 2026Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone PaymentsBy Alex Philippidis, GEN Edge, June 16, 2026First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine DataGEN, June 9, 2026CRISPR Shreds Undruggable Cancer Cells with PrecisionBy Fay Lin, PhD, GEN Edge, June 8, 2026New mRNA Delivery Platform Restores Muscle Function in DMD ModelsGEN, June 11, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

Ragnhild Ørstavik deler siste nytt fra andre vitenskapelige tidsskrifter. Forskere gjør fremskritt i utvikling av en vaksine mot andesvirus (1). Hvor stor er spredningsfaren av smittsomme sykdommer på store arrangementer (2, 3)? Bør pasienter med alvorlig brannskade få høydosebehandling med vitamin C (4, 5)? Og er det egentlig grunnlag for å anbefale kalsium og vitamin D for å forebygge fall og osteoporotiske brudd (6, 7)? Leger i Japan trekker seg stille unna de vakttunge fagene og går mot fag som plastisk kirurgi (8). Har politiske tiltak noen effekt mot overvekt og fedme hos barn og unge (9, 10)? Kan CRISPR-genredigering bistå i behandling av den sjeldne sykdommen hereditært angioødem (11)? Forskning tyder på at BCG-vaksinen kan redusere insulinbehovet hos pasienter med type 1-diabetes (12). Og til slutt en personlig tekst om å hjelpe pasienter rammet av opioidkrisen i USA (13). Se hele litteraturlista her: https://tidsskriftet.no/2026/06/podkast/redaktorens-hjorne-110-andesvirus-vitamin-c-og-brannskader-crispr Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no. Stetoskopet produseres av Helena Heimer Rognstad, Caroline Ulvin Johansson, Are Brean, Ragnhild Ørstavik og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.Jingle og lydteknikk: Moderne media Coverillustrasjon: Stephen Lee See omnystudio.com/listener for privacy information.

About this episode:   A group of students from suburban Atlanta has developed a new method for detecting Lyme disease using the gene-editing tool CRISPR. In this episode: why there's such a desperate need for a new diagnostic, how the students' model works, and why it's so promising for the treatment of Lyme and other diseases.  Guest:  Nicole Baumgarth, PhD, DVM, is Bloomberg Distinguished Professor in Molecular Microbiology and Immunology and the director of the Lyme and Tickborne Disease Research and Education Institute at the Johns Hopkins Bloomberg School of Public Health.  Sankalp Yeleti is a recent graduate of Lambert High School and a rising freshman at New York University, where he plans to study biomolecular science.  Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing—CBS News  Lancet—Lambert iGEM 2025 Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Welcome, Massimo Banzi of SuperModerno and co-founder of Arduino Introduction and SuperModerno: Massimo introduces himself as a “friendly nerd” and discusses his new project, SuperModerno The project aims to explain the “behind the scenes” of technology to prevent people from becoming “slaves to the platform” The History of Technology: Massimo expresses his passion for technology’s history, emphasizing non-American innovators to show Europeans they can also lead in technology, citing the UK-based origins of the Arm processor The Legacy of Olivetti: He highlights Olivetti (founded in 1908), which moved from typewriters to creating the Programma 101, the first desktop computer used by NASA to compute orbits for the Apollo program Design as a Differentiator: Olivetti was the first tech company to apply design to everything (products, posters, and architecture) This inspired Massimo's concept of the “invisible touch”, the idea that consistent, intentional design creates a unique connection with users and gives a company a competitive edge The Interaction Design Institute Ivrea (IDII): Massimo’s path led him to IDII, located in the former Olivetti research building, where he transitioned from a two-week sabbatical to a four-year stay Learning by Making: To help students with no electronics background, Massimo drew on how he learned as a seven-year-old (“learning by making”) to remove the friction of interacting with technology The Founding Team: He met Tom Igoe (ITP) and David Cuartielles, and they realized students were afraid to be creative because they feared “blowing up” expensive tools like the Basic Stamp The “Pizza and a Beer” Price Point: Massimo aimed for a hardware cost of 20 Euros, roughly what a student would spend on a pizza and a beer, to encourage experimentation Building the Platform: Along with David Mellis, the team adapted Processing (a language for artists) by “surgically” replacing Java with C++ to create the Arduino IDE Ivrea Manufacturing: Leveraging the industrial base of Ivrea and Torino (the “Detroit of Italy”), Massimo was able to find local PCB manufacturers and assemblers just a short drive away From Hacking to AVR: Massimo's early work involved hacking satellite TV PIC chips for soccer fans, but mentor Bill Verplank encouraged him to use AVR microcontrollers because they could be programmed simply in C Enabling Creators: Massimo shares stories of how Arduino enabled others, such as Josef Prusa, who started with Arduino as a teenager before building his global open-source 3D printer company The Innovation of Simplicity: Massimo argues that Arduino’s true innovation is the user experience This is measured by the “Time to First Blink”, the goal for a user to go from downloading software to blinking an LED in five minutes Standardization and “The Core”: Arduino became an ad-hoc standard by providing a compatibility layer across different microcontrollers Massimo believes in having a “small slice of a really large pie” by allowing other architectures to work within the ecosystem Hardware Architecture and the “Lasagna”: Inspired by the PC104 format, the board uses a layered approach where modules stack like a lasagna The “Shield of a King”: The name Arduino comes from King Arduino of Ivrea; David Cuartielles suggested that since the board was named after a king, the add-on modules should be called “Shields” Hardware Design Choices: The board fits a credit card size (to stay within the free version of Eagle software) and is blue because that color was thought to be less tiring for workers’ eyes Happy Accidents: The unique shape was chosen to be “ourselves instead of everyone else” During the design process, Massimo inadvertently moved a connector by half a step, creating an offset header that they kept for consistency after the first few thousand were made The Discovery of Auto-Reset: During a workshop in Germany, Massimo solved the frustration of manual resets by soldering a capacitor to the DTR pin, allowing the software to trigger the reset automatically The US Market and Legal Battles: Tom Igoe's adoption of Arduino at NYU helped the US become the project’s single biggest market This growth led to a difficult legal battle for control of the brand against a former partner Support from Arm: Massimo credits Arm Ltd (and CEO Simon Segars) for providing the strategic support that allowed the founders to regain control of the company. Massimo believes this is the first time he has talked about the role of Arm in the difficult legal process. Industrial and AI Expansion: Partnerships with Intel and Microsoft (Windows 10 IoT) led to early forays into TinyML (AI on small boards) back in 2017 The Qualcomm Acquisition: In October 2025, Qualcomm acquired Arduino, which Massimo sees as essential for bringing “advanced silicon” into the family to handle the increasing complexity of technology The “Arduino Formula” and Layering: Massimo views Arduino as a formula for simplification that can be applied to anything, including complex Linux machines like the Uno Q This is achieved by building in layers, where beginners use high-level abstractions and experts can “strip away” layers to reach the bare metal The Future Vision: Massimo looks forward to the “Arduino Formula” being applied to new fields, stating he is waiting for someone to develop an “Arduino for biology” using CRISPR and DNA technology

BUFFALO, NY – June 17, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 8, 2026, titled “DHHC3 interferes with antitumor immunity in melanoma cells.” The study was led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler from the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. Melanoma is one of the most aggressive forms of skin cancer and is highly influenced by interactions between tumor cells and the immune system. Although modern immunotherapies have transformed treatment for many patients, researchers continue to search for molecular mechanisms that enable tumors to evade immune attack and continue growing. In this study, researchers investigated DHHC3, a protein acyltransferase that regulates protein palmitoylation and helps maintain cellular redox balance. Previous studies had linked elevated DHHC3 expression to poor outcomes in several cancers, but its role in melanoma and anti-tumor immunity remained unclear. To explore this question, the team used CRISPR gene editing to eliminate DHHC3 expression in B16F10 melanoma cells. Loss of DHHC3 caused a marked increase in oxidative stress and cellular senescence, as demonstrated by elevated TXNIP expression, increased reactive oxygen species levels, and enhanced expression of senescence-associated markers. Full press release - https://www.oncotarget.net/2026/06/17/protein-linked-to-melanoma-growth-may-suppress-the-bodys-natural-anti-tumor-immune-response/ DOI - https://doi.org/10.18632/oncotarget.28880 Correspondence to - Martin E. Hemler - martin_hemler@dfci.harvard.edu, and Chandan Sharma - csharma@mgh.harvard.edu Abstract video - https://www.youtube.com/watch?v=QQhP2VhzKSE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28880 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Thomas is joined by Dr. Eric Jaffe, biologist, dinosaur enthusiast, and high school biology teacher, for a conversation that starts with a deceptively simple question: what are biological definitions actually doing? It turns out that biology is far more like history than math, and that difference has enormous consequences for anyone trying to weaponize phrases like "the biological definition of sex." Dr. Jaffe walks through why definitions in inductive sciences are descriptive, not prescriptive, and what that means for species, chromosomes, fungi, LeBron James, and trans people. "Exceptions aren't the exceptions in biology. They are built into what we call biological systems." Plus: Patreon Q&A questions on alien DNA, how new chromosomes evolve, the 97% chimp figure, CRISPR vs. what came before, and Trump's research budget cuts. Cells at Work (anime recommended by Dr. Jaffe) Project Hail Mary (film referenced) Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailIf you enjoyed this deep dive on cloning and genetic modification, hit subscribe, drop a comment with your take — should we bring back the woolly mammoth? — and share the episode with the friend who still thinks Walt Disney's head is in a freezer.Cloning and genetic modification get blended together constantly in pop culture, so this episode breaks down what's actually real, what's a myth, and how we got from a frog tadpole in 1952 to dire wolf pups in 2025.Brian, Thomas, and producer Corey (it's Corey's birthday) walk through the full history and science of cloning — admitting up front they're not scientists, just three guys following a rabbit hole that started with a family cloning their dog, CRISPR edits, and the Lone Star tick. From there it turns into a surprisingly thorough tour of how copying and editing life actually works.The episode untangles the four ideas people constantly confuse: cloning (a genetic copy, same DNA), genetic modification / gene editing (changing genes, like CRISPR), de-extinction (reviving a lost species), and chimeras (mixing cells from two species). With that foundation set, the crew traces the timeline from Yves Delage's 1895 nuclear transplantation concept and Hans Spemann's 1938 "fantastical experiment," through the first nuclear transfer in 1952, John Gurdon's Nobel Prize work, and Dolly the sheep — the first mammal cloned from an adult cell, born July 5, 1996.If you've ever wondered whether you can really clone your pet, this one answers it: it's real, it's commercial, and it's expensive. They cover the actual companies and price tags, why a clone is not a resurrection, and why the Humane Society pushes back on the practice. The conversation also gets into man-animal hybrids — the bizarre real story of Soviet scientist Ilya Ivanov — and busts the myth that Stalin wanted an army of ape-man super soldiers.This is for anyone curious about CRISPR, stem cell medicine, de-extinction headlines, and the ethics underneath all of it: human-animal chimeras grown for transplant organs, the 100,000+ Americans on the organ waiting list, and whether reproductive human cloning should stay banned. Expect the science (telomeres, Large Offspring Syndrome, the brutal 1–5% survival rate) alongside the kind of unfiltered, off-the-rails commentary the show is known for.By the end you'll understand why the 2025 "dire wolf" isn't really a dire wolf, what the Bucardo's grim record actually was, and why mules — and ligers — can't be bred the way you'd think. It's a fast, funny, fact-checked crash course in one of the wildest fields in modern science.New episodes of The Days Grimm Podcast drop regularly — history, science, true crime, and whatever rabbit hole Tom drags everyone into next.TIMELINE:00:00 — Cold open & welcome (Corey's birthday)01:58 — Today's deep dive: cloning and genetic modification02:07 — "We're not scientists" disclaimer03:04 — Why Tom picked this: CRISPR, the Lone Star tick & a cloned dog04:34 — 1895: the first nuclear transplantation concept06:21 — The 4 things people confuse: cloning, gene editing, de-extinction & chimeras07:07 — Why the 2025 "dire wolf" is really edited gray wolf11:16 — 1952 leopard frogs & John Gurdon's Nobel work12:30 — Dolly the sheep and why she mattered14:00 — Why mules (and ligers) can't reproduce16:46 — How cloning actually works (somatic cell nuclear transfer)20:26 — What we've cloned so far + first primate clones (2018)21:54 — Can you clone your pet? The real companies and prices23:51 — A clone is not a resurrection + welfare concerns25:01 — Man-animal hybrids & the Soviet Ivanov story27:00 — Chimeras for medicine and pig organ transplants32:00 — De-extinction & the Bucardo: "extinct twice"33:47 — The black-footed ferret success story34:30 — 2025 dire wolf pups & the woolly mouse37:00 — Telomeres, Large Offspring Syndrome & failure rates39:30 — Ethics: mammoths, pets, chimeras & human cloning41:00 — Busting the Walt Disney frozen-head myth42:30 — Wrap-up[The Days Grimm Podcast Links]- YouTube: https://www.youtube.com/c/TheDaysGrimm- Our link tree: linktr.ee/Thedaysgrimm- GoFundMe account for The Days Grimm: https://gofund.me/02527e7c [The Days Grimm is brought to you by]Sadness & ADHD (non-medicated)

More than just a game—Knicks overcoming odds in game 4 comeback is a parable of resilience; A one and done lifetime cholesterol fix via gene modification; Will cataract surgery interfere with benefits of light exposure? Do amounts of vitamin A in various supplements taken together court the risk of toxicity? Smartphones and social media create real harm for adolescents; Experts determine the exact right amount of sleep down to the minute—but is it overreach? 

Episode 377 Considered too dangerous and unreliable a few years ago, the technology for gene editing babies is advancing fast. Improved methods of using CRISPR gene editing are making the technique safer and more targeted. But does that mean we should be creating designer babies? A new, more powerful version of CRISPR has already saved lives by correcting cells in children linked to leukaemia. But editing human embryos is a different story - and less safe. Despite this, researchers have been studying whether it's possible. To discuss the obstacles that still need to be overcome and the ethical challenges, Rowan Hooper is joined by reporter Michael Le Page.To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a recap of the top 10 posts on Hacker News on June 12, 2026. This podcast was generated by wondercraft.ai (00:30): Statement on US government directive to suspend access to Fable 5 and Mythos 5Original post: https://news.ycombinator.com/item?id=48511072&utm_source=wondercraft_ai(01:58): AI agent bankrupted their operator while trying to scan DN42Original post: https://news.ycombinator.com/item?id=48500012&utm_source=wondercraft_ai(03:26): CRISPR tech selectively shreds cancer cells, including "undruggable" cancersOriginal post: https://news.ycombinator.com/item?id=48505231&utm_source=wondercraft_ai(04:55): Claude Fable is relentlessly proactiveOriginal post: https://news.ycombinator.com/item?id=48498573&utm_source=wondercraft_ai(06:23): Nobody ever gets credit for fixing problems that never happened (2001) [pdf]Original post: https://news.ycombinator.com/item?id=48498385&utm_source=wondercraft_ai(07:52): Open source AI must winOriginal post: https://news.ycombinator.com/item?id=48511908&utm_source=wondercraft_ai(09:20): Kimi K2.7-Code: open-source coding model with better token efficiencyOriginal post: https://news.ycombinator.com/item?id=48502347&utm_source=wondercraft_ai(10:49): "Don't You Just Upload It to ChatGPT?"Original post: https://news.ycombinator.com/item?id=48507278&utm_source=wondercraft_ai(12:17): Electric motors with no rare earthsOriginal post: https://news.ycombinator.com/item?id=48510010&utm_source=wondercraft_ai(13:46): How to setup a local coding agent on macOSOriginal post: https://news.ycombinator.com/item?id=48507020&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

The career path -- M.S. in Neuroscience to filmmaking -- is a wholly original one and so is his filmmaking. His second feature, PONDEROSA (2026), is a comedy-horror film that looks at American masculinity in a way I've never seen before. It is a gift to watch -- beginning to end -- not because I understood everything going on, but because I didn't.The best type of filmmaking should challenge you and make you think differently about the world around you. Mission accomplished here by Rob, with brilliant actors by his side. I'm texting my friend with a neuroscience degree, telling him to get on over to Tribeca and make a film!In this episode, Rob and I talk about:going from CRISPR engineer to filmmaking;how PONDEROSA came about and the trickiness of describing the film;what his experiences at prominent film festivals taught him;how he got some of the best actors out there -- Bill Camp; Alexis Bledel -- to work on his film;how he did the score and music FIRST and then edited accordingly;how he balances directing and producing;what's next for him.Rob's Indie Film Highlight: THE MISCONCEIVED (2026) dir. by James N. Kienitz WilkinsLinks:Follow Rob On Instagram

Send us Fan MailSomebody left the heat on in the Midwest, and we're feeling every degree of it. We start with the kind of summer heat wave that messes with your sleep, forces the air conditioner decision, and makes you stare at the electric bill like it's a personal betrayal. Then we lighten it up with a “supposedly accurate” weather tour that lets you compare your day to places like Beijing, Moscow, the Australian Plains, Phoenix, Spokane, Tokyo, and our own backyard in Southern Illinois complete with humidity, UV index, wind, visibility, and air quality.The mood turns when we talk about severe storms and outages up north, and we share a quick note for soccer fans about the upcoming FIFA World Cup 2026 schedule and the unique North America hosting setup. After that, we shift into an earthquake report with weekly totals and the sobering reality of major quakes, including a 7.8 earthquake near the Philippines, the tsunami warning, and what it's like to watch aftershocks stack up when people are already shaken and vulnerable. One of the hardest parts is admitting it out loud: earthquake warnings still aren't where they need to be, and that gap costs real people real safety.We close with the question that ties a surprising list of sci-fi movies together from Gattaca to Wrath Of Khan: genetic modification. CRISPR gene editing isn't just a plot device anymore, and headlines about embryo genome editing raise the same moral dilemma those stories keep shouting at us: just because we can, should we. If you care about heat waves, disaster news, earthquake preparedness, bioethics, and where genetic engineering might lead, you'll find plenty to wrestle with here.Subscribe, share the show with a friend, and leave a review if our mix of curiosity, faith, and oddball reporting gives you something to think about.Support the show I hope you enjoy the show!  If you find value in our show,Pray for us! Send Us Positive vibes.Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow.Contact Us. Email: theuglyquackingduck@gmail.com. Send Us Fan Mail: Under our description on any podcast player you will find a link you can text us or record a message. Leave a voice message: Just letting us know you are out there listening is a big boost!Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costsAnyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce  Email:          theuglyquackingduck@gmail.comWebsite:     https://theuglyquackingduck.com/

Send us Fan MailSomebody left the heat on in the Midwest, and we're feeling every degree of it. We start with the kind of summer heat wave that messes with your sleep, forces the air conditioner decision, and makes you stare at the electric bill like it's a personal betrayal. Then we lighten it up with a “supposedly accurate” weather tour that lets you compare your day to places like Beijing, Moscow, the Australian Plains, Phoenix, Spokane, Tokyo, and our own backyard in Southern Illinois complete with humidity, UV index, wind, visibility, and air quality.The mood turns when we talk about severe storms and outages up north, and we share a quick note for soccer fans about the upcoming FIFA World Cup 2026 schedule and the unique North America hosting setup. After that, we shift into an earthquake report with weekly totals and the sobering reality of major quakes, including a 7.8 earthquake near the Philippines, the tsunami warning, and what it's like to watch aftershocks stack up when people are already shaken and vulnerable. One of the hardest parts is admitting it out loud: earthquake warnings still aren't where they need to be, and that gap costs real people real safety.We close with the question that ties a surprising list of sci-fi movies together from Gattaca to Wrath Of Khan: genetic modification. CRISPR gene editing isn't just a plot device anymore, and headlines about embryo genome editing raise the same moral dilemma those stories keep shouting at us: just because we can, should we. If you care about heat waves, disaster news, earthquake preparedness, bioethics, and where genetic engineering might lead, you'll find plenty to wrestle with here.Subscribe, share the show with a friend, and leave a review if our mix of curiosity, faith, and oddball reporting gives you something to think about.Support the show I hope you enjoy the show!  If you find value in our show,Pray for us! Send Us Positive vibes.Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow.Contact Us. Email: theuglyquackingduck@gmail.com. Send Us Fan Mail: Under our description on any podcast player you will find a link you can text us or record a message. Leave a voice message: Just letting us know you are out there listening is a big boost!Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costsAnyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce  Email:          theuglyquackingduck@gmail.comWebsite:     https://theuglyquackingduck.com/

One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.

In this episode of Moving Medicine Forward, Dr. Robert Fisher—one of the pioneers of modern transplant surgery—explores the rapidly advancing field of xenotransplantation and why it may represent a true turning point in medicine.From CRISPR-driven genetic engineering to breakthroughs in immunosuppression and scalable organ production, Dr. Fisher breaks down how decades of research are converging to make cross-species organ transplants a clinical reality.The conversation also dives into what this means for patients, how it could transform transplant access, and the critical role of rigorous, collaborative clinical research in translating breakthrough science into real-world care.01:23 Dr. Fisher's path into transplant surgery03:05 Why xenotransplantation is reaching a turning point (CRISPR + immunosuppression)04:47 Advances enabling scalability, safety, and compatibility 08:32 Ethics, risks, and clearing misconceptions10:27 Real-world patient impact and clinical considerations 13:10 Logistics, coordination, and clinical execution15:49 New immunosuppression strategies driving success17:44 Collaboration, ethics, and managing risk 20:49 Eliminating waitlists: expanding access to transplant22:54 Milestones toward adoption and future outlook

Episode SummaryIn the Season 2 finale of Breathless, host Jeremie Saunders tackles the ultimate question facing the Cystic Fibrosis (CF) community: Are we finally on the verge of a true cure? Growing up sick, Jeremie developed a psychological "immunity" to the repetitive promise that a cure was "just around the corner." But today, the conversation is fundamentally different.This episode takes us out of the pharmacy and directly into the laboratories where researchers are transitioning from small-molecule symptom management to structural gene editing. Featuring Dr. Bowen Li (University of Toronto), Dr. Paul Eckford (Chief Scientific Officer, CF Canada), and Kelly Grover (CEO, CF Canada), we pull back the curtain on the grueling reality of scientific research—described as "pushing a boulder up a hill with chopsticks." We explore how the global proof of concept from COVID-19 mRNA vaccines has turbocharged CF research, how CRISPR molecular scissors are being engineered to permanently rewrite genetic typos, and how Machine Learning is drastically accelerating the timeline to reach the final 10% of the community.Main Topics & Key Moments1. The Cost of Hope & The Ground ShiftThe Practiced Optimism: Jeremie details the emotional exhaustion of childhood hope cycles, where promised breakthroughs consistently failed to materialize, leading to a defensive "self-preservation" mindset in his twenties.A New Vocabulary: Why current scientific progress is materially different. For the first time, data-driven researchers are using definitive terms like functional cure, mutation-agnostic, and restoring normal function at the source.2. The Grind of the ArchitectureChopsticking the Boulder: Dr. Bowen Li describes the quiet, unglamorous reality of the lab at 8:00 PM on a Tuesday, where progress is measured in microscopic, hard-won inches.The Lazarus Effect vs. The Temped Joy: CEO Kelly Grover recalls an early advocacy trip to Ottawa with a profoundly ill young man, contrasting his miraculous post-Trikafta transformation with the sobering reality of meeting patients who remain devastatingly sick.3. The Molecular Typo: Nonsense MutationsThe Broken Text: While Trikafta acts as a structural prop for a wobbly, misfolded protein, it is entirely useless for patients with "nonsense mutations."The Cellular Stop Sign: Dr. Bowen Li explains that in these rare variations (such as the W57X mutation discussed in previous episodes), the cell hits a premature stop sign in the middle of reading the genetic sentence. The protein is cut off too early and never forms, leaving nothing for modulator drugs to attach to.4. Photocopies and Vaults: mRNA vs. CRISPRThe Vault Analogy: Dr. Li frames human genetics simply: DNA is the master cookbook safely locked inside the nucleus vault. You cannot remove the book, but you can create a temporary photocopy of a single page to take to the kitchen. That photocopy is mRNA.The Platform Revolution: A historical look at mRNA, from its discovery by Brenner and Crick in the 1960s to Katalin Karikó's underfunded, decades-long battle to chemically stabilize the molecule. The global deployment of COVID-19 vaccines served as the ultimate medical proof of concept, opening the floodgates for respiratory disease mapping.The Lipid Nanoparticle Trojan Horse: To get delicate mRNA past the lung's natural "bouncers" (mucus and cilia), scientists wrap it in a micro-engineered fat bubble designed to slide through sticky blockages and hit targeted cells.CRISPR Molecular Scissors: Moving beyond temporary photocopies, CRISPR edits the master cookbook itself. Hijacked from a bacterial immune defense system discovered in yogurt cultures, Jennifer Doudna and Emmanuelle Charpentier engineered the Cas9 protein to act as scissors guided by genetic GPS. Modern iterations—like base editing and prime editing—can cleanly correct a single letter in the double helix without fracturing the strand. Hosted on Acast. See acast.com/privacy for more information.

We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Most of biotech runs on a tiny handful of "model" organisms — E. coli, baker's yeast — while millions of wild species sit unstudied in what scientists call microbial dark matter. In this episode, Karl and Erum sit down with Henry Lee, co-founder of Cultivarium, to explore why the future of synthetic biology depends on learning to grow, study, and engineer the organisms we've ignored. Henry breaks down the real difference between model and non-model organisms, why simply culturing a new microbe can take years, and how Cultivarium is standardizing growth recipes and building an open digital platform so any researcher can work with strains that were once impossible to handle. Along the way: a fistulated cow, a spectacular failure that ultimately cracked the genetics of cement-making bacteria, extreme microbes that could free fermentation from fresh water, and Cultivarium's evolution from a Focused Research Organization into a "Frontier Research Contractor." The conversation closes on the state of American science — funding, public trust, and AI — plus the America's Living Library Act and a quick-fire round on archaea, overused buzzwords, and whether we're alone in the universe. Before the interview, Karl and Erum spill some biotech tea on "Biotech Barbie" Cathy Tie and unpack what the video game Stray gets right about engineered microbes escaping into the wild.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) — Summer vibes & a little biotech gossip: meet "Biotech Barbie"(00:07:42) — What a video game about a lost cat teaches us about runaway microbes(00:12:38) — How Henry went from building circuits to falling for biology(00:16:25) — So what actually is a "non-model" organism?(00:22:30) — Yes, we really talk about a cow with a window in its stomach(00:25:40) — Step inside Cultivarium: incubators, recipes & happy accidents(00:33:35) — Borrowing nature's best ideas: fungi, archaea & glowing jellyfish(00:39:15) — The failure that taught us everything (a cement-making bacteria story)(00:43:45) — Could the ocean fuel the future of fermentation?(00:48:45) — Real talk: science funding, public trust & the promise of AI(00:53:25) — Reinventing how big science gets funded — and a library of life(01:00:10) — Dream organisms, pet-peeve buzzwords & "are we alone?"(01:05:55) — Karl & Erum unpack their favorite momentsLinks and Resources:CultivariumBiosphere Project27. Charting the Unexplored Microverse for Biological Gold with CULTIVARIUM's Nili Ostrov147. Shhh…They're Talking: Holoclara's Dr. Andrea Choe Tunes Into Worm Signals for Health98. Gotta Get Them All: bitBiome's Quest to Decode All Microbes with Yuji Suzuki183. The American Biotech Blueprint: Senator Todd Young on Biodiversity as National SecurityKathy Tie Biotech Barbie Gene EditingStray - A Synthetic Biology Video GameBioInnovations Events - For 25% off use code: Grow EverythingTopics Covered:non-model organisms, microbial dark matter, model organisms, Cultivarium, industrial biotechnology, microbial engineering, DNA repair, CRISPR, fermentation, frontier research contractorHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Un grupo de científicos de la Universidad de Georgia quería entender mejor la vasopresina, una hormona clave en la cooperación, la amistad y el autocontrol. Para ello, desactivaron sus receptores en un grupo de hámsters usando la tecnología CRISPR. Esperaban roedores más pacíficos y gregarios. Obtuvieron justo lo contrario: pequeñas alimañas violentas dispuestas a despedazar a cualquier congénere. El resultado abre una pregunta incómoda: ¿y si la agresividad fuese el comportamiento por defecto de los mamíferos, y solo una hormona nos separa del caos? Hablamos de bioquímica, de futuras terapias para individuos violentos… y de aplicaciones militares que dan bastante más miedo que cualquier película de terror. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

What is the future of gene editing with CRISPR? Has AI changed mathematics forever? Will we find other civilizations in the universe? What if we've been wrong about dark energy all along? These are just a few of the big, bold questions we'll be exploring in the new season of The Joy of Why. Mathematician Steven Strogatz and physicist Janna Levin are back as your hosts for these and other conversations that explore the frontiers of basic science and mathematics. Each episode features an in-depth conversation in which Steven or Janna sits down with a leading scientist or mathematician to unpack one big idea or area of research. The two hosts also chat together throughout each episode, sharing their own thoughts, reactions, and questions.

Our guests today are Ryan Jackson and Ned Weinshenker. We discuss a new CRISPR system that can be used to selectively kill cells, and some recent breakthroughs in the growing technology.

We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap

We are hearing a lot about gene Therapy and CRISPR technology. Mark's guest shared some wonderful healing examples and where we are going with this amazing science. Hear this from Dr. Lindsay George from CHOP about the exciting new health world ahead of us all on The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

In today's episode, I break down DNA, where it is found, and what it represents from a scientific and biblical standpoint. I discuss CRISPR, the genome, gene drives, and methylation. Is this innocent innovation or planned biological control and rewriting? #DNA #blood #Biblical #creation #CRISPR #genedrives #consent #coersion #control #accountability #GOD

Most receptors come with a history. Remulate came with a name — and almost nothing else. Dr. Beatriz Redondo, group leader at the University of Leipzig, has spent the last nine years building the first systematic characterization of adhesion GPCRs in Drosophila, including three receptors so new they were named after condiments. What she's constructing isn't just a receptor profile — it's a method for doing discovery when the tools don't exist yet.Dr. Redondo uses CRISPR, genetic tagging, and in vivo behavioral assays to place and characterize adhesion GPCRs in a system where generations turn over in weeks. Her work on remulate — a neuronal adhesion GPCR with a human ortholog linked to vascular malformations and blood-brain barrier dysfunction — is among the first of its kind in any organism.Key takeaways:Why Drosophila remains a productive system for receptor discovery in the genomics eraHow CRISPR and epitope tagging replace antibody-based tools for understudied GPCRsWhat nocifensive behavior in larvae reveals about remulate's neuronal functionHow basic science in an insect model connects to vertebrate disease biologyWhat it looks like to characterize a receptor from scratch — with no prior literature to build onDr. GPCR University — live and on-demand courses for scientists working on real discovery problems: https://www.ecosystem.drgpcr.com/gpcr-universityThis episode is supported by Eurofins DiscoverX and GeneTex: https://www.ecosystem.drgpcr.com/eurofins-discoverx | https://www.ecosystem.drgpcr.com/genetex

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Este episodio especial está diseñado para sorprender a los oyentes con hechos reales sobre el futuro de la salud humana, alejándose de los fenómenos inexplicables tradicionales del programa para centrarse en los asombrosos avances de la ciencia médica actual. El guion explora cómo la convergencia de los datos masivos, la inteligencia artificial y la biología molecular ha acelerado la innovación de manera sin precedentes. A lo largo del programa, se detallan hitos revolucionarios que ya son una realidad, como las terapias génicas hiperpersonalizadas con CRISPR, el uso de la tecnología de ARN mensajero para combatir tumores específicos y los xenotrasplantes con órganos de cerdos modificados genéticamente. Además, se aborda la detección precoz del cáncer mediante biopsias líquidas, los enfoques científicos para la longevidad y los esfuerzos de la medicina regenerativa para construir nuevos tejidos desde cero. Sin embargo, el episodio mantiene una postura crítica y honesta al discutir también las sombras de esta revolución, cuestionando el alto costo de los tratamientos, la desigualdad en la investigación global y los profundos dilemas éticos que surgen al intervenir en la naturaleza humana. #LaRuedaDelMisterio #FuturoDeLaMedicina #CienciaYSalud #Biotecnología #MedicinaPersonalizada #CRISPR #Bioética laruedadelmisterio2010@gmail.com ®© La Rueda del MisterioEscucha este episodio completo y accede a todo el contenido exclusivo de La Rueda del Misterio. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/4754

Check out BeerBiceps SkillHouse Courses Here - https://www.bbskillhouse.comFor all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsCheck out my Mind Performance app: Level SuperMindLink:- https://level4665.u9ilnk.me/d/F1ZOZV4OnTShare your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Join the Level Community Here:https://linktr.ee/levelsupermindcommunityFollow BeerBiceps SkillHouse's Social Media Handles:YouTube: https://www.youtube.com/@BeerBicepsSkillHouseInstagram: https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comFollow Dr. Niraj Rai's Social Media Handles:-Instagram: https://www.instagram.com/nirajbiotechgju X: https://www.instagram.com/nirajbiotechgjuIn this special episode 506th of The Ranveer Show, we are joined by Dr. Niraj Rai, a leading scientist in genetics, who shares deep insights on DNA, Human Evolution, Indian Ancestry, and Health. This episode takes you into the mysteries of our genetic code, the history of Indian populations, and how our environment shapes our biology.In this conversation with Dr. Niraj Rai, we talk about the 98% Mystery DNA, the impact of inbreeding in Indian communities, the "Heart Attack Gene" specific to South Asia, and the future of CRISPR technology. We also understand how genetics can reveal our true history, from the Indus Valley Civilization to the migrations that shaped modern India.This episode also covers the Gut Microbiome, the science behind the Gotra system, the evolutionary role of proteins, and how stress and happiness affect our genetic expression. We explore the differences between ancient and modern humans and the possibility of superhuman traits hidden within us.(00:00) – Start of the episode(01:59) – Dr. Niraj Rai Returns to TRS(02:55) – The Infinite Mystery of Human DNA(05:15) – Secret of the "Warrior Clan" Proteins(08:27) – Are we 99.9% the same?(11:49) – Why Chimpanzees are 6x Stronger than Humans(14:08) – AI & the Future of Genetic Engineering(16:52) – Epigenetics: How Mood changes your Biology(19:39) – Is the Indian Genetic Code deteriorating?(21:47) – Biohacking with Stem Cells & CRISPR(25:46) – The Harsh Truth about Caste-based Inbreeding(28:30) – Why Indians are prone to Heart Attacks(32:33) – Natural Selection & Virus Outbreaks(35:52) – What did Ancient Indians really eat?(42:54) – Is Autism the next stage of Human Evolution?(47:27) – Why Humans are losing Physical Strength(51:13) – The Genetic selection for Fair Skin in India(55:26) – CRISPR: Technology to create Super-Humans(1:07:27) – Why Punjabis have "Milk-Digesting" Genes(1:11:28) – Ancient Invasions & Genetic Mixing(1:18:33) – Scientific Logic behind the Gotra System(1:22:32) – Roman & Persian DNA in South India(1:26:14) – Criminal Genes & Inherited Trauma(1:28:37) – Hypoxia Therapy for Depression(1:34:25) – End of the episode

Ginny Yurich sits down with Dr. Sina McCullough for one of the most eye-opening conversations we've had on The 1000 Hours Outside Podcast. Sina shares how a devastating health collapse led her from a PhD in nutrition to questioning everything she thought she knew about the American food system. Together they unpack why ultra-processed food is so cheap, how the farm bill reshaped the modern grocery store, and what's really happening with gene-edited foods, pharmaceutical crops, CRISPR technology, and the hidden chemicals most families never even realize they're consuming. But this episode is not rooted in fear. It's about remembering that our daily choices still matter, that real food can help the body heal, and that ordinary people have more power than they've been led to believe. This conversation will make you look at your pantry, your plate, and your family's future differently. Sign up for the Two Days of Truth here Check out Dr. Sina McCullough's new book: Hands Off My FoodCheck out the Beyond Labels podcast Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailSubscribe and unleash your inner science goblin. We see you. We respect it.What happens when your DNA makes a typo?In this episode of Wildly Curious, Katy Reiss and Laura Fawks Lapole dive into the strange, fascinating world of genetic mutations—the tiny changes in DNA that can shape evolution, alter proteins, create disease, or sometimes do absolutely nothing at all. From harmless genetic quirks to serious inherited disorders, this episode breaks down some of the most important mutation types in a way that actually makes sense.

Dr. Adam Brockman brings you the stories redefining modern medicine—from CRISPR's new “molecular paper shredder,” a biotech breakthrough that targets sick cells with surgical precision, to a “crystal ball” blood test that may predict your biological future with uncanny accuracy. Discover how nature and innovation are teaming up: from Spirulina's B12 revolution for plant-based eaters, to Lyme's surprising connection with Alzheimer's, and the radical plan to stop infection at its source by vaccinating mice instead of humans. It's science meets real-world transformation—tune in and learn how to stay years ahead of your biology.Health Headlines of the WeekHealth Alternative of the WeekHealth Outrage of the WeekHealth Mystery of the Week

Fungi are “nature's biological recycling machines,” says guest Vayu Hill-Maini, a former chef turned bioengineer. That is, they take waste and turn it into good things. Hill-Maini now melds his scientific and culinary skills to create new foods, but also medicines, faux leather, pigments and other valuable products from mushrooms and molds. He uses CRISPR gene editing technology to “domesticate” these fungi – removing off-flavors and increasing nutritional content to make new-age cheeses, burgers, salami, and more. “We call it the DBTL cycle – design, build, taste, learn,” Hill-Maini tells host Russ Altman about his creative process on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Vayu Hill-Maini Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Vayu Hill-Maini, a professor of bioengineering at Stanford University. (00:03:33) From Chef to Bioengineer How Hill-Maini's culinary background led him to study food through science. (00:05:23) Building a Lab with a Kitchen Why his Stanford lab combines bioengineering research with culinary experimentation. (00:07:32) What Are Fungi? A primer on yeasts, molds, mushrooms, and their role in food and medicine. (00:10:22) Domesticating Fungi How humans have shaped fungi over thousands of years. (00:14:23) Mushrooms as a Food Source The nutrients, proteins, vitamins, and beneficial molecules found in fungi. (00:16:21) Fungi as Biological Recyclers Using fungi to turn food waste, agricultural waste, and other materials into useful products. (00:18:22) Making Waste-Based Foods Desirable Why taste, emotion, and culinary design matter for sustainable foods. (00:20:22) Engineering Delicious Fungi Using genetics and CRISPR to improve flavor, nutrition, and usability. (00:22:50) Gentle Genetic Tweaks Making small changes to reduce off-flavors or enhance useful traits. (00:23:46) Design, Build, Taste, Learn How the lab moves between kitchen and bench science to improve foods. (00:24:06) Chefs in the Lab How culinary collaborators help guide research and creativity. (00:28:58) Fungi-Based Materials The potential to create textiles, leather alternatives, and building materials. (00:31:03) Future In a Minute Rapid-fire Q&A: sustainability, students, and the promise of fungi. (00:33:25) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the AgCulture Podcast, Paul sits down with Bob Miller, founder of Miller Hybrids, to unpack what it really takes to build a seed company in an industry dominated by global giants. From his early days in plant breeding to launching his own company in the middle of industry consolidation, Bob shares a perspective that challenges much of how modern seed is developed, tested, and sold.This conversation dives deep into why most seed is bred for “perfect conditions” instead of real farms, how Miller Hybrids tests genetics differently to create more stable performance, and why conventional corn is quietly making a comeback. Bob also breaks down the economics behind traits, the real role of GMOs, and where farmers may be overpaying for protection they don't actually need.If you've ever wondered whether bigger companies actually mean better seed—or what the future of genetics, CRISPR, and farm profitability really looks like—this episode will make you think differently about every seed decision you make.MEET THE GUESTBob Miller is a respected corn breeder and the founder and owner of Miller Hybrids, a family-owned seed company based in Kalona, Iowa.Born on a dairy and crop farm in northwest Ohio, Miller developed an early fascination with corn hybrids and their ability to handle stress and maximize yields. He built a distinguished career as a corn breeder with major seed companies, including Syngenta,where he developed successful commercial inbred lines and hybrids. His work emphasized improved emergence, yield stability, and drought tolerance.In 2005, he founded Miller Hybrids (originally B.O.B. Seeds, standing for "Best of the Best") to create a more hands-on, farmer-focused operation. As owner, president, and research director, Miller leads the company's breeding and testing programs. He develops corn hybrids tailored for the average farm, rigorously testing them across diverse soil types, stress conditions, and real-world environments like corn-on-corn rotations.Miller is deeply committed to empowering farmers. He believes in building reliable products that raise farm averages rather than chasing only top-end yields in ideal conditions. His family company (with his wife Pam) emphasizes personal attention, direct access to the breeder, and genetics that deliver stable, high performance for everyday growers.Through Miller Hybrids, Bob continues his lifelong passion for practical plant breeding, blending decades of industry expertise with the independence of a family business to support American agriculture.To learn more about Miller Hybrids, check out their website: https://www.millerhybrids.com/

Glen McGugan, Ph.D., Director of ASM's Mechanism Discovery Unit, discusses how curiosity‑driven research—from parasite virulence to CRISPR and complex microbial systems—drives tomorrow's breakthroughs.  Ashley's Biggest Takeaways Mechanism discovery,encompasses all of the foundational basic research across the microbial sciences and is essential for all advances in microbial science. Many transformative technologies (e.g., CRISPR) originated from curiosity-driven, basic research rather than immediate practical goals. McGugan's experience as a Program Officer at NIH provided him with a broad perspective on the research pipeline, from basic science to clinical trials, and highlighted the importance of supporting early-career scientists. Developing therapeutics for parasitic diseases is particularly challenging due to complex life cycles and limited financial incentives for pharmaceutical companies; much of the progress relies on government and philanthropic funding. ASM's Mechanism Discovery Unit serves as a neutral hub to convene interdisciplinary stakeholders, foster collaboration, and advance fundamental research. Safeguarding future breakthroughs in the microbial sciences depends on the involvement of and connections between researchers, policymakers, funders and industry partners to close gaps between discovery, implementation and impact.  

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Trevor Martin, Co-Founder and CEO of Mammoth Biosciences, a company at the forefront of next-generation CRISPR technologies. Co-founded alongside Nobel Prize-winning scientist Jennifer Doudna, Mammoth is building a platform to both detect and cure disease by harnessing the natural diversity of CRISPR systems.Trevor's journey into biology was anything but conventional—initially drawn to physics and chemistry, he discovered biology through an interdisciplinary lens that revealed its true complexity and potential for engineering. That shift ultimately led him to Stanford, where he began exploring the intersection of genetics, computation, and real-world impact.From there, this conversation traces the founding of Mammoth, the decision to pursue entrepreneurship over academia, and the ambition to build a generational biotech company—not just a single-asset success. Trevor shares how CRISPR is evolving from a breakthrough technology into a scalable platform capable of addressing a wide range of genetic diseases, with the potential to fundamentally reshape human health.At its core, this episode explores the convergence of science, entrepreneurship, and persistence—highlighting what it takes to translate cutting-edge research into real therapies, and why the next decade of biology may redefine what it means for genetics to determine our future.

Joined by Heidi Luv (Unfiltered Rise) to discuss blood doping, golden blood, Rh factor, and CRISPR technology. We delve into types of blood doping, military involvement, super soldiers, DARPA, and much more! Follow Heidi at https://open.spotify.com/show/4pzqktZNcGNZhzAeF9Zd3Q?si=BLmOZCUrTfe2o5XuGqYW7g www.unfilteredrisepodcast.com IG @unfilteredrise_podcast   X @UnfilteredRise On Patreon  #blooddoping #goldenblood #CRISPR #DNA #military #DARPA #supersoldiers #EPO #Autologous #syntheticoxygencarriers #bloodclots #damage #diseases #ATP #Rh #internationalregistry #blood #bloodcard #bloodlines #aliens #Nephilim

I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.Source Links for Further ResearchI. Rare Disease Advocacy and Funding (Conflicts of Interest)[TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)[TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)[TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)[TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)[NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)[NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/) [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)[Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)[NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)II. Gene Therapy (CRISPR), Risks, and Regulation [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)[CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)[CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)[FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)III. Vaccines, Toxins, and Environmental Amplification [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)[Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/) [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)[Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)IV. Alternative and Holistic Approaches[Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-(mtor)-pathway)[Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)[Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)[Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)contact Jill: pjlacy6@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

The full quad is back and we're getting right into the tech drama: AI backlash (from Reese Witherspoon to everyday skepticism), breakthrough science like CRISPR entering its “it actually works” era, and major power shifts across tech — from Apple succession chatter to Jensen Huang's leadership moments and the brewing battle between OpenAI and Elon Musk. They squad digs into SpaceX IPO dynamics, the rise of “traces” data as the next AI battleground, and what happens when AI gives more people the power to build. Chapters:0:17 — Welcome Back: Full Quad Edition1:07 — Creatine, AI Stuffies, and the Opening Chaos4:37 — Breakthrough Prize & CRISPR Finally Working5:47 — One-of-One Gene Therapy Becomes Real7:07 — The AI Backlash Is Real8:47 — UBI vs. Meaning: The Real Debate10:57 — Jensen's “I Didn't Wake Up a Loser Today” Moment12:47 — Apple Succession: Tim Cook → John Ternus16:17 — Asset Prices vs. Reality21:17 — Elon vs. OpenAI: The Trial27:07 — SpaceX IPO: Biggest in History?29:27 — xAI, Cursor, and the $60B Bet36:07 — Traces Data: The Next AI Battleground40:07 — Workplace Surveillance & Employee Data48:27 — Who Gets to Build? (6B Users vs. 50M Builders)51:07 — AI: Equalizer or Concentrator?We're also on ↓X: https://twitter.com/moreorlesspodInstagram: https://instagram.com/moreorlessYouTube: https://youtu.be/bjePLXg64n0Connect with us here:1) Sam Lessin: https://x.com/lessin2) Dave Morin: https://x.com/davemorin3) Jessica Lessin: https://x.com/Jessicalessin4) Brit Morin: https://x.com/brit

In part two of this two part episode, Jack continues their look into the dubious practice of “de-extinction” this time as it is pushed in the 21st century by Colossal BioSciences. Created in 2019 by Ben Lamm and George Church, Colossal aims at making extinction, as well as the endangered species list, a thing of the past using CRISPR technology. Claiming to have revived the Dire Wolf and Red Wolf, the company actually has been more successful in massive PR campaigns and paying off critics than reversing species death. But who benefits when people believe that the ecosystem can be preserved through test tubes rather than policy aimed at protecting endangered animals? You guessed it: wealthy sociopaths who see traditional conservation efforts as a barrier to total planetary domination. Gimmie Truth by Brad Abrahams https://bradabrahams.net/independent/gimme-truth-be7s6 Subscribe for $5 a month to get all the premium episodes: www.patreon.com/qaa Check out our new podcast series network Cursed Media! Spectral Voyager Season 2 is releasing now! Binge the entirety of Truly Tradly Deeply by Annie Kelly and Megan Kelly as well as Science in Transition by Liv Agar and Spencer Barrows: cursedmedia.net Produced by Liv Agar & Corey Klotz. Theme by Nick Sena. Additional music by Pontus Berghe. Theme Vocals by THEY/LIVE (instagram.com/theyylivve / sptfy.com/QrDm). Cover Art by Pedro Correa: (pedrocorrea.com) qaapodcast.com QAA was known as the QAnon Anonymous podcast.

Weichert details the downfall of Charles Lieber, a Harvard scientist and DARPA researcher recruited by the Thousand Talents Program to mirror his nanotechnology work in Wuhan, later convicted for making false statements and hiding Chinese bank accounts. The discussion shifts to CRISPR technology and He Jiankui's controversial genetic splicing on human twins, which reportedly resulted in unintended brain augmentations. Weichert warns that China views biotechnology as "dual-use," meaning advancements intended for civilian health are simultaneously being weaponized by the People's Liberation Army. (2)1937 SHANGHAI IMPERIAL JAPANESE NAVY FLAGSHIP

After talking about health as we always do because we're old, we pivot to diet — specifically veganism. Cori, who has never cared about animal rights, gamely steel-mans an argument in favor, while Nina, whose bleeding heart has caused anemia and possibly brittle bones, fearfully argues against. Along the way we cover tribes, rituals, purity, CRISPR, evolution, Lierre Keith, lactose tolerance, lactation intolerance, the Bible, abattoirs, eggs, nuts, Jordan Peterson, cults, The Liberation Pledge, and how Nina accidentally killed a bat when she was 17.Since recording this on Passover 2026 (release delay 85% Cori's fault) Nina worked through more of her apostasy, first writing The Law of Conservation of Evil and then Vegan Appreciation Day. She's done now.Links:The Vegetarian Myth by Lierre Keith: https://www.lierrekeith.com/book-ex_the-vegetarian-myth.phpSoylent (Creamy Chocolate is the only good flavor): https://www.amazon.com/Soylent-Chocolate-Protein-Replacement-Bottles/dp/B08H6FB43L?th=1Nina's Fecebook solicitation: https://www.facebook.com/nina.paley/posts/pfbid0EcMpKSUVyGm6356iEw8VeJXzRJhSP5X3YyVZkDKrUAVrMrYC4oUR3fMriQ8vA2xtlNina's poll on Spinster: https://spinster.xyz/@ninapaley/posts/B4tQFS5G2srXYSm1LcNina's poll on Twitter:Jordan Peterson's Lion Diet: https://liondiet.com/the-diet-updated-march-2018/The Liberation Pledge: https://veganfta.com/blog/2022/11/16/what-is-the-liberation-pledge-and-how-hard-is-it/Vegan TERFFles (out of stock) (password: vegan): https://store.ninapaley.com/product/vegan-terffles/Vegan Appreciation Day: https://ninapaley.com/2026/04/09/vegan-appreciation-day/The Law of Conservation of Evil: https://ninapaley.com/2026/04/04/the-law-of-conservation-of-evil/ Get full access to Heterodorx Podcast at heterodorx.substack.com/subscribe

 In 2023, the FDA approved the first gene therapies to help treat people with sickle cell disease. The treatment is for patients 12 years and older, but what if you could use this technology before someone is born? That’s what some researchers, and others, believe is the hope for the future. The idea is to use CRISPR, a technology used to edit the genes of living beings, during in vitro fertilization. It is much easier said than done, but could be possible in theory. Ashley Smart is the associate director of the Knight Science Journalism Program at MIT. He is also a senior editor at Undark and reported on embryonic gene editing for the publication. He joins us to share how these treatments and technologies might work, as well as the current challenges and limitations.

MAGIC MYTHOS AND MAGA  - 04.13.2026 - #931 BestPodcastintheMetaverse.com Canary Cry News Talk #931 - 04.13.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable   This Episode was Produced By:   Executive Producers Sir LX Protocol Baron of the Berrean Protocol***   Producers of TREASURE (CanaryCry.Support) Rebecca T, Cage Rattler Coffee   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   SIR IKE MEGA BOX GIVEAWAY - Rating/Review, screenshot, send to Sir Ike CanaryCrySupplyDrop@gmail.com   TRUMP/BIBLICAL 9:49 Trump Deletes Post With Image Depicting Himself as Jesus After Backlash (Variety) → Gonz post comparing Trump to Pope with crying McConaughey Clip: Trump at WH addresses the image after food delivery *   WW3 37:37 Trump Truth on Friday "Great Reset" (Truth) CENTCOM blockade on all Iranian ports CLIP: Full Blockade on Iranian Ports announced CLIP: Tankers on there way itro gulf of America "The Purpose of a System is what it Does" (Wiki)   ELON/BEAST SYSTEM 1:19:56 Elon and magic thread Triumphal Arch    EXECUTIVE PRODUCERS 2:02:15 SIR IKE SUPPLY DROP GIVEAWAY! - sir ike speakpipe speakpipe - nomemprunte,  In honor of your new baby emu, I am running a new special this month. People can take an extra 5% off all Emu Wrangler Roasts with code: BABYEMU  Toph Challenge   UFO 2:12:20 Missing nuclear official becomes TENTH person tied to dark pattern surrounding US secrets (DailyMail)    BEAST SYSTEM 2:29:15 Apple Says Southern Lebanon Villages Weren't Removed From Maps (Wired)   CRISPR/DNA/FOOD 2:40:09 CRISPR CITRUS → Gonz post about CRISPR edited orange trees, 300K in Florida   CALLED IT 2:47:54 Ready to rumble? Hunter Biden challenges Trump's sons to cage match (Reuters)   PRODUCERS 2:55:45 END 3:07:46

Xenotransplantation—the use of organs from other species to treat human disease—has long existed at the intersection of science fiction and surgical innovation. While early efforts were marked by limited success and ethical controversy, recent advances in genetic engineering, immunosuppression, and organ preservation have brought the field closer than ever to clinical reality.In this episode of Behind the Knife, we are joined by Dr. Joshua Mezrich to explore the history, science, and future of xenotransplantation. Through a narrative lens, we trace the evolution of transplantation from its earliest experimental days to the modern era of gene-edited porcine organs, highlighting key breakthroughs, ethical challenges, and the pioneers who shaped the field. We also examine the current state of clinical trials and what xenotransplantation may mean for the future of organ availability and transplant practice.Hosts - Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan  - Joshua Mezrich, MD, Professor, University of Wisconsin School of Medicine and Public HealthLearning Objectives By the end of this episode, listeners will be able to:- Describe the historical evolution of xenotransplantation, including the primate and early porcine eras - Explain the key immunologic and biologic barriers to xenotransplantation, including hyperacute rejection and the role of natural antibodies - Summarize major scientific advances that enabled modern xenotransplantation, including cloning and CRISPR-based gene editing - Discuss recent clinical experiences and ongoing trials of xenotransplantation in humans -  Evaluate the ethical considerations and societal implications of xenotransplantation - Consider the potential role of xenotransplantation in addressing organ shortage and reshaping transplant eligibility and allocationCheck out Dr. Mezrich's new book! https://www.amazon.com/Every-Living-Creature-Xenotransplantation-Change-ebook/dp/B0FH14LF6K***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6***Surgical Instrument FlashCards: https://app.behindtheknife.org/premium/surgical-instrument-flashcards Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Bill Maher sits down with neuroscientist Andrew Huberman to explore how smartphones, artificial light, and social media are reshaping how we think and connect. Huberman explains why morning sunlight and dark nights are critical for sleep, metabolism, and overall health. The two also dig into biohacking, peptides, and Big Pharma incentives, separating what's real from what's hype. They tackle shifting behavior, shrinking attention spans, and the future of health—from mRNA cancer treatments to CRISPR gene editing—along with more unsettling territory, including Jeffrey Epstein's connections to the scientific world. In the end, they land on a striking truth: “We don't relate to each other anymore—we relate through a screen." Support our Advertisers: High blood pressure can't wait. Get 20% off at ⁠https://www.120life.com⁠ and use code RANDOM Subscribe to the Club Random YouTube channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/c/clubrandompodcast?sub_confirmation=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Watch episodes ad-free – subscribe to Bill Maher's Substack: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://billmaher.substack.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to the podcast for free wherever you listen: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/ClubRandom⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Buy Club Random Merch: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://clubrandom.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit https://podcastchoices.com/adchoices ABOUT CLUB RANDOM Bill Maher rewrites the rules of podcasting the way he did in television in this series of one on one, hour long conversations with a wide variety of unexpected guests in the undisclosed location called Club Random. There's a whole big world out there that isn't about politics and Bill and his guests—from Bill Burr and Jerry Seinfeld to Jordan Peterson, Quentin Tarantino and Neil DeGrasse Tyson—talk about all of it.  For advertising opportunities please email: PodcastPartnerships@Studio71us.com ABOUT BILL MAHER Bill Maher was the host of “Politically Incorrect” (Comedy Central, ABC) from 1993-2002, and for the last fourteen years on HBO's “Real Time,” Maher's combination of unflinching honesty and big laughs have garnered him 40 Emmy nominations. Maher won his first Emmy in 2014 as executive producer for the HBO series, “VICE.” In October of 2008, this same combination was on display in Maher's uproarious and unprecedented swipe at organized religion, “Religulous.” Maher has written five bestsellers: “True Story,” “Does Anybody Have a Problem with That? Politically Incorrect's Greatest Hits,” “When You Ride Alone, You Ride with Bin Laden,” “New Rules: Polite Musings from a Timid Observer,” and most recently, “The New New Rules: A Funny Look at How Everybody But Me Has Their Head Up Their Ass.” FOLLOW CLUB RANDOM https://www.clubrandom.com https://www.facebook.com/Club-Random-101776489118185 https://twitter.com/clubrandom_ https://www.instagram.com/clubrandompodcast https://www.tiktok.com/@clubrandompodcast FOLLOW BILL MAHER https://www.billmaher.com https://twitter.com/billmaher https://www.instagram.com/billmaher Learn more about your ad choices. Visit podcastchoices.com/adchoices

If a species is horrible enough, do we have the right to kill it forever? Seventy years ago, a nightmare parasite feasted on the live flesh of warm-blooded creatures in North America: the screwworm. That is, until a young scientist named Edward F. Knipling discovered a crucial screwworm weakness and hatched a sweeping project to wipe them out. Knipling's seemingly zany plan to spray screwworms out of planes all over the continent— with US taxpayer money— succeeded, becoming one of humanity's biggest environmental interventions ever.  Today, screwworms have been gone so long that none of us in North America even remember them. But now, they're coming back. And they're forcing us to ask: in an era of climate change and rapid mass extinction— should we kill off a species on purpose?  Special thanks to James P. Collins, Max Scott, Amy Murillo, Daniel Griffin, Phil Kaufman, Katie Barnhill, Arthur Caplan, Ron Sandler, Yasha Rohwer, Aaron Keefe, Gwendolyn Bogard, Maria Sabate, Meredith Asbury, and Joanne Padrón CarneyEPISODE CREDITS:  Reported by - Sarah Qari with help from - Latif Nasser Produced by - Sarah Qari Sound design contributed by - Sarah Qari Fact-checking by - Emily Krieger EPISODE CITATIONS: **The latest information on screwworm outbreaks and precautions: screwworm.gov Videos: Oral history interviews of Edward F. Knipling: here (https://zpr.io/njhMedFN5jsZ) and here (https://zpr.io/VQReQbfznCrq)  Podcasts: Here's a Spotify playlist (https://zpr.io/PNMEM274G7vh)  of all of our Golden Goose-inspired episodes! Sam Kean's podcast The Disappearing Spoon – his episode about screwworms is called The Screwiest and Perhaps Most Original Idea of the 20th Century (https://zpr.io/UYf6dR2yG3eN)  Our episode on CRISPR & gene drives (https://zpr.io/UYf6dR2yG3eN)  New to Radiolab? Check out our Radiolab Starter Kit (https://zpr.io/QpPnrHAZVQLR)  playlist of all-time favorite episodes! Articles: Sarah Zhang's latest piece in The Atlantic: American Milk Has Changed (https://zpr.io/xebbdq2MWV4L)  Her most recent piece on screwworms: The ‘Man-Eater' Screwworm Is Coming (https://zpr.io/ECmjCs7ScbS4)  Her initial reporting on screwworms: America's Never-Ending Battle Against Flesh-Eating Worms (https://zpr.io/PNMEM274G7vh)  Gregory Kaebnick's paper (https://zpr.io/yqNC3q5FbCcq)  about screwworm eradication in Science Archival materials:  The USDA's Screwworm Eradication Records (https://zpr.io/dY7zuVdGYKjf) contain lots of cool images and letters Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices